MAAT (MAAT) News
Track canonical SquawkNews coverage tagged to MAAT, MAAT. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
CHMP maintains negative opinion on MaaT Pharma’s MaaT013
MaaT Pharma said the CHMP upheld its negative opinion on the CMA for MaaT013 (Xervyteg®) after re-examination.
REGULATION | Sep 18, 2026, 05:30 AM UTC
L
MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 (Xervyteg®) Following Re-Examination for its Conditional Marketing Authorization Application in Europe
Regulatory News:MaaT Pharma (EURONEXT: MAAT — the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients w
NEWS | Sep 15, 2026, 05:30 AM UTC